Roche Obesity Shot Led to 18% Weight Loss in Study (1)

Jan. 27, 2026, 8:08 AM UTC

Roche Holding AG said patients on its experimental shot lost 18% more weight than those who got placebo in a study that will help set the stage for the Swiss drugmaker to compete in the lucrative obesity market.

Almost half of the volunteers treated with the highest dose shed 20% or more of their body weight by week 48 of the mid-stage trial, Roche said Tuesday.

The results are the first in a raft of mid-stage results due out this year from five key experimental drugs as Roche pushes to reach the top three of the obesity market despite ...

Learn more about Bloomberg Law or Log In to keep reading:

See Breaking News in Context

Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.

Already a subscriber?

Log in to keep reading or access research tools and resources.